SCHEMBL4414575

SCHEMBL4414575

CCOC(=O)CNCCNS(=O)(=O)c1nc(-c2ccccc2)c(C)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
CYP2C9 P11712 4/20 0.49
CYP2C19 P33261 4/20 0.49
HSD17B10 Q99714 3/20 0.49
CYP1A2 P05177 3/20 0.49
RARA P10276 1/20 0.45
RARB P10826 1/20 0.45
RARG P13631 1/20 0.45
ALOX5 P09917 1/20 0.41
MAPK1 P28482 1/20 0.41
LTA4H P09960 3/20 0.40
RORC P51449 1/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
CYP2D6 P10635 1/20 0.40
DHODH Q02127 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419660 0.87 ADORA3 (0.53) ALDH1A1CYP2C9CYP2C19HSD17B10CYP1A2
SCHEMBL4418662 0.82 LTA4H (0.43) ALDH1A1HSD17B10LTA4HHPGDTRPM8
SCHEMBL609992 0.81 MAPK1 (0.50) ALDH1A1HSD17B10MAPK1MEN1KMT2A
SCHEMBL27657728 0.77 ALDH1A1 (0.47) ALDH1A1CYP2C9CYP2C19HSD17B10CYP1A2
SCHEMBL4423896 0.74 KMT2A (0.38) ALDH1A1CYP2C9CYP2C19CYP1A2LTA4H
SCHEMBL4417022 0.74 CA1 (0.39) ALDH1A1LTA4HHPGDKMT2AGAA
SCHEMBL3136533 0.73 CA2 (0.42) ALOX5MEN1KMT2A
SCHEMBL4413761 0.72 MAPT (0.41) ALDH1A1HSD17B10HPGDMEN1KMT2A
SCHEMBL3137752 0.72 POLB (0.39) ALDH1A1CYP2C19HSD17B10CYP1A2HPGD
SCHEMBL4411288 0.70 DDX3X (0.42) ALDH1A1HSD17B10MAPK1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651642-B1 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2009-11-04 EP disclosed
US-7211668-B2 PNA monomer and precursor PANAGENE, INC. (KR) 2007-05-01 US disclosed
EP-1651642-A4 PNA MONOMER AND PRECURSOR PANAGENE INC (KR) 2006-11-29 EP disclosed
EP-1651642-A1 PNA MONOMER AND PRECURSOR Panagene Inc. (KR) 2006-05-03 EP disclosed
US-20050026930-A1 PNA monomer and precursor PANAGENE, INC. (KR) 2005-02-03 US disclosed
WO-2005009998-A1 PNA MONOMER AND PRECURSOR PANAGENE INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026930-A1 PNA monomer and precursor RNGTT, POLL, NSUN3 ALDH1A1 3450/4885CYP2C9 4514/4885CYP2C19 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.